Back to Search
Start Over
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+acute myeloid leukemia
- Source :
- Blood Advances; October 2024, Vol. 8 Issue: 19 p5091-5099, 9p
- Publication Year :
- 2024
-
Abstract
- •Gilteritinib maintenance therapy after allogeneic HCT in FLT3-ITDAML is not associated with any difference in HRQOL compared with placebo.•Despite a higher incidence of adverse events, gilteritinib was not associated with any patient-reported impact of side effects.
Details
- Language :
- English
- ISSN :
- 24739529 and 24739537
- Volume :
- 8
- Issue :
- 19
- Database :
- Supplemental Index
- Journal :
- Blood Advances
- Publication Type :
- Periodical
- Accession number :
- ejs67227018
- Full Text :
- https://doi.org/10.1182/bloodadvances.2024013746